NEW YORK— British drugmaker GlaxoSmithKline is looking into allegations of bribery within its operations in Jordan and Lebanon. On Monday the BBC reported that GlaxoSmithKline PLC is facing a bribery investigation in Poland, where a sales representative allegedly paid doctors to prescribe the company's asthma drug Seretide.» Read More
Good morning all. Deborah Taft continues to hold the top position, but she is losing ground. And there's a new number two; Jason Kaplan. Jason gains 2nd place on his Worthington Industries trade forcing Chad Mazeika into 3rd place with only small gains on Mariner Energy and Sonus.
An FDA Advisory Committee voted 17-0 saying Dendreon's Provenge for prostate cancer is "reasonably safe". And it voted 13-4 saying there's "substantial evidence" that it's efficacious. At first the efficacy question was phrased by the FDA like this: "Does the submitted data establish the efficacy of (Provenge) in the intended population?" Call it semantics, but as they started going around the room it sounded like it might go down with that language.
GlaxoSmithKline said Thursday it has submitted a biologics license application for Cervarix, its cervical cancer candidate vaccine, to the U.S. Food and Drug Administration.
Hi folks. Here a look at the latest stock performance. Quick turnarounds seem to be paying off for several stocks, but obviously, not all. Downgrades and business news (see Beazer Homes below) certainly affect what's happening. Note the "replacements" at the S&P in the first paragraph. Okay, here are the stats with some notes on why the stocks are where they are.
Good morning. Deborah Taft and Chad Mazeika maintain their stranglehold on the two top positions of the Leaderboard. Deborah continues in the lead with a portfolio value of $2,585,726.30 up $3k from Tuesday's total of $2,582,726.3 on bonus bucks alone. After Deborah's trade on CVTX she was all in cash before executing two buys Wednesday...
Embargo-gate at the ACC Scientific journals and medical groups employ media embargoes on studies that are to be published or presented. The common practice gives reporters like me a chance to read and digest the information in advance, interview researchers and experts, maybe talk to patients so that when the embargo lifts full and accurate stories will air, run in the papers or cross the wires. It also gives the journals and medical groups a way to manage the news cycle and get more media bang for their publication or conference. Such was supposed to be the case at this week's American College of Cardiology conference in New Orleans.
Shares of pharmaceutical firm Dendreon leaped on Wednesday following a CNBC report about a planned Thursday Food and Drug Administration hearing that could determine the fate of a prostate cancer drug from the company.
Good morning. Deborah Taft continues in the lead with a portfolio value of $2,582,726.3, up $366,000 Tuesday, from Monday's value of $2,216,726.30. Deborah's gamble on the ever-active CV Therapeutics paid off and secured her lead position. She went all in on Monday with a buy of 300,000 shares of CVTX at $6.75, and it looks like she caught a bottom...
Plaintiff Frank Schwaller sued Merck after his wife, Patricia, took Vioxx for 20 months for shoulder pain before dying from a heart attack in August 2003.
Most of our celebs had a slow day Monday, but James Cromwell "has been a machine" as someone said. Not only is he buying stocks, he's putting those bonus bucks to work--something the other celebs--and you non-celebs should be using to your advantage. Willie Garson used them to put Johnny Bench back in last place.
Hey folks. Here's the best performing trades by % gain from Friday's close to Monday's close: Biosite--If you bought on Friday at $55.38 and held/sold on Monday with a close of $83.80, the contestant gained 51.32% on the trade (9 out of the 10 current weekly leaders as of Monday's close bought BSTE on Friday).
French drug maker Sanofi Aventis’ board is split over whether to acquire U.S. pharmaceutical company Bristol-Myers Squibb in a deal that could be worth $54 billion, London newspaper The Times reported.
Take a company that’s being managed into the ground, add an activist investor to stir things up, and you’ve got a stock that should go higher. Tonight, Cramer’s got a play that fits the model.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
More than half a million people a year with chest pain are getting an unnecessary or premature procedure to unclog their arteries because drugs are just as effective, suggests a landmark study that challenges one of the most common practices in heart care.
Merck and Schering-Plough said on Monday they were beginning development of a cholesterol-lowering product that would combine their Zetia drug with Pfizer's Lipitor.
Pfizer's abandoned experimental drug torcetrapib failed to slow clogging of heart arteries even as it boosted "good" cholesterol levels, according to a study presented Monday.
Beckman Coulter, which makes products for biomedical tests, said on Sunday it would acquire Biosite for about $1.55 billion to expand its presence in the market for diagnosis and assessment of heart failure.
AstraZeneca's Crestor cholesterol drug slowed thickening in the neck arteries of people at low risk for heart attacks and strokes, but it failed to reverse thickening as researchers had hoped it would.
When Rodman and Renshaw biotech analyst Mike King told me "Genentech was gonna get its geek on," at its annual analyst meeting today I didn't realize how spot on he might be. Today the company took a deep dive into the science of its drug research and development pipeline...cabbage looper worms and all. I'm not kidding. But the ultimate geek factor came from the company's Chairman and CEO Art Levinson.